New Inhibitors of Bcr-Abl Based on 2,6,9-Trisubstituted Purine Scaffold Elicit Cytotoxicity in Chronic Myeloid Leukemia-Derived Cell Lines Sensitive and Resistant to TKIs

• Autors principals: Thalia Delgado (Autor), Denisa Veselá (Autor), Hana Dostálová (Autor), Vladimír Kryštof (Autor), Veronika Vojáčková (Autor), Radek Jorda (Autor), Alejandro Castro (Autor), Jeanluc Bertrand (Autor), Gildardo Rivera (Autor), Mario Faúndez (Autor), Miroslav Strnad (Autor), Christian Espinosa-Bustos (Autor), Cristian O. Salas (Autor)
• Format: Llibre
• Publicat: MDPI AG, 2024-05-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Bcr-Abl is an oncoprotein with aberrant tyrosine kinase activity involved in the progression of chronic myeloid leukemia (CML) and has been targeted by inhibitors such as imatinib and nilotinib. However, despite their efficacy in the treatment of CML, a mechanism of resistance to these drugs associa...